fbpx
Concept 2 Clinic Inc.
  • Home
  • Solutions
    • CMC – Chemistry, Manufacturing, and Control
    • Opportunity Assessment
    • Regulatory / Quality
    • Pre Clinical
    • Clinical
    • Project Management
    • Financial
  • About Us
    • Our Team
    • Preferred Partners
    • Become A Partner
  • Resources
    • Case Studies
    • Industry News
    • Pharma Blog
  • Careers
  • Contact Us
  • Free Consultation
  • Search
  • Menu

AVROBIO, Inc. Announces Updated Clinical Data from Ongoing Phase 1 and Phase 2 Studies for AVR-RD-01 Gene Therapy for Fabry Disease

You are here: Home / Concept2Clinic News / AVROBIO, Inc. Announces Updated Clinical Data from Ongoing Phase 1 and...

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 6, 2019– AVROBIO, Inc. (Nasdaq: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced clinical trial updates from the ongoing investigator-sponsored Phase 1 clinical study and the AVROBIO-sponsored Phase 2 clinical trial of AVR-RD-01. AVR-RD-01 is an investigational gene therapy candidate designed to treat Fabry disease by inserting the GLA gene that encodes functional α-galactosidase A (AGA, the enzyme that is deficient in patients with Fabry disease) with the goal of enabling continuous endogenous AGA production and distribution to tissues and organs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190206005307/en/

Corporation

1.416.805.8573
info@concept2clinic.com

Refine Naturals

Our Location

Lower Level, 360 Hwy 7 East
Richmond Hill, Ontario, L4B 3Y7, Canada

Office Hours: Monday to Friday, 9:00 am to 4:00 pm EST

Our Solutions

  • Solutions
    • CMC – Chemistry, Manufacturing, and Control
    • Opportunity Assessment
    • Regulatory / Quality
    • Clinical
    • Pre Clinical
    • Project Management
    • Financial

Categories

  • Concept2Clinic News
  • Pharmaceutical Blog

Recent Posts

  • Vaccine Development
  • Clinical Trial Monitoring
  • CMC – Chemistry, Manufacturing, and Control
  • Clinical Trials
© Copyright - Concept 2 Clinic
Milestone Pharmaceuticals Announces First Patient Randomized in the Phase 3... AVROBIO, Inc. Announces FDA Clearance of Investigational New Drug Application...
Scroll to top

Become A Concept2Clinic Partner

Join one of the worlds strongest biotech forces

Fill out the information below and one of our qualified representatives will get back to you shortly.